1Marshall BJ . The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology. AmJ Gastroenterol,1991, 86:16-25.
2Cengiz N, Uslu Y, Giik F , et al. Acute renal failure after overdose of colloidal bismuth subcitrate. Pediatr Nephrol, 2005, 20: 1355- 1358.
3Teepker M, Hamer HM, Knake S, et al. Myoclonic encephalopathy caused by chronic bismuth abuse. Epileptic Disord,2002,4:229-233.
8Malfertheiner P, Bazzoli F, DelchierJ C, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet, 2011, 377: 905- 913.
9Megraud F, Roberts P, Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter, 2000,5 :222-226.
10Eichler I. The bismuth-encephalopathy - a new pathological syndrome (author's transl). Wien Klin Wochenschr, 1979,91: 314-320.
4Malfertheiner P,Bazzoli F,Delchier JC,et al.Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium,metronidazole,and tetracycline given with omeprazole versus clarithromycinbased triple therapy:a randomised,open-label,noninferiority,phase 3 trial.Lancet,2011,377(9769):905-913.
5Luther J,Higgins PD,Schoenfeld PS,et al.Empiric quadruple vs.triple therapy for primary treatment of Helicobacter pylori infection:Systematic review and meta-analysis of efficacy and tolerability.Am J Gastroenterol,2010,105(1):65-73.
6Fuccio L,Minardi ME,Zagari RM,et al.Meta-analysis:duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.Ann Intern Med,2007,147(8):553-562.
